KLRA Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
106.3M
-12.4%
121.4M
R&D
84.7M
-16.2%
101.1M
SG&A
21.7M
+6.7%
20.3M
Operating Income
-106336000
+12.4%
-121373000
EBITDA
-106235000
+12.4%
-121272000
Net Income
-95665000
+14.1%
-111307000
EPS (Basic)
$-0.74
+32.1%
$-1.09
EPS (Diluted)
$-0.74
+32.1%
$-1.09
Shares (Diluted)
129.7M
+26.8%
102.2M
Kailera Therapeutics (KLRA) — Financials